Biomea Fusion reports Phase 1 weight loss data for oral GLP-1 drug
Tweet Send to a Friend
Biomea Fusion, Inc. (Nasdaq: BMEA) released Phase 1 clinical trial results for BMF-650, an investigational oral small-molecule GLP-1 receptor agonist ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




